摘要
目的观察生脉注射液联合健择加顺铂方案治疗晚期非小细胞肺癌的临床效果及其减毒增效作用。方法将52例晚期非小细胞肺癌患者随机分为中药加化疗组和单纯化疗组各26例。化疗组予健择1000 mg/m2第1、8天30 min静滴,顺铂75 mg/m2第1天静滴,21 d为1个周期;中药加化疗组于化疗前3 d生脉注射液60 ml加入5%GS 500 ml静滴。每天1次连用3周,两个周期后按照WHO实体瘤近期客观疗效评定标准进行评价。结果中药加化疗组和单纯化疗组近期有效率为46.15%和42.31%,中药加化疗组的Karnorfsky评分增加9例,单纯化疗组增加3例,中药加化疗组体重明显增加,外周血白细胞及血小板下降和贫血发生率明显较单纯化疗组低。结论生脉注射液能提高健择加顺铂方案化疗患者的生存质量,改善临床症状,减轻化疗后骨髓抑制。
Objective To observe the clinical efficiency and side effect of Shengmai injection combined with Gemcitabine plus Cisplatin for advanced non-small cell lung cancer（NSCLC）. Methods Fifty two patients with NSCLC were randomized two groups, chemotherapy for 26 patients, herb plus chemotherapy for the rest. Gemcitabine （1000 mg/m^2） were administered to the former group by intravenous drip for thirty minutes on the lrst and the 8th day, Cisplatin （75 mg/m^2） were given on the lrst day and the 21rst days for a cycle;for the latter three days before chemotherapy the patients received Shengmai injection （60 ml） containing 5 % GS 500 ml once a day for three weeks. Efficiency was evaluated after two-cycle treatment was performed. Results The current effective rate in the two groups were 46. 15% and 42.31%. For three patients in the former group Karnorfsky grade increased, while nine in the latter one. The former group gained more weight. The count of peripheral white blood cells, platelet and hemoglobin in the latter mai injection can effectively improve living quality of myelosuppression after chemotherapy. group were much lower. Conctusion patients, relieve clinical symptom and Shengreduce
出处
《苏州大学学报（医学版）》
CAS
北大核心
2006年第4期631-633,共3页
Suzhou University Journal of Medical Science
